U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,785.50
    +1.20 (+0.07%)
     
  • Silver

    23.11
    -0.39 (-1.66%)
     
  • EUR/USD

    1.1320
    +0.0108 (+0.96%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3338
    +0.0018 (+0.14%)
     
  • USD/JPY

    113.3300
    -2.0090 (-1.74%)
     
  • BTC-USD

    54,375.25
    -2,703.20 (-4.74%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bristol Myers Squibb BMY announced that the European Commission (EC) has approved its blockbuster immuno-oncology drug, Opdivo (nivolumab), for another indication.

The drug is now approved for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) as a second-line treatment. The drug is approved for this after prior fluoropyrimidine- and platinum-based combination chemotherapy.

The approval was based on results from the phase III ATTRACTION-3 study, sponsored by Ono Pharmaceutical Co., Ltd. of Japan, which demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) in patients who received Opdivo as compared to those receiving chemotherapy. The safety profile for Opdivo was favorable compared with chemotherapy and consistent with previously reported studies of the drug in other solid tumors.

On a worldwide basis, esophageal cancer is the seventh most common cancer and the sixth most common cause of death from cancer.

We note that Opdivo is already approved in the United States and Japan, for the second-line treatment of patients with unresectable advanced, recurrent or metastatic ESCC. Approval in additional geographies increases the sales potential of the drug.

Opdivo is approved in several countries for various indications — unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy, advanced renal cell carcinoma (RCC), adult patients with classical Hodgkin lymphoma (cHL), and recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), among others. It is also approved for various indications in combination with Yervoy.

Shares of Bristol-Myers have decreased 1.5% so far this year, in-line with the industry’s decline. 

Approval of additional indications should boost Opdivo’s sales, which were not impressive in the year so far. Notably, the drug faces stiff competition from Mercks MRK Keytruda and Roches RHHBY Tecentriq, particularly for the NSCLC indication.

Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech space is Halozyme Therapeutics, Inc. HALO, which sports a Zacks Rank #1 (Strong Buy), presently. You can see the complete list of today’s Zacks #1 Rank stocks here.

Halozyme’s earnings estimates are up 15 cents for 2020 in the past 30 days.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research